The Enterprise Value as of December 2024 (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) is 356.78M

According to Monte Rosa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 356.78M. This represents a change of 20.59% compared to the average of 295.87M of the last 4 quarters.

Monte Rosa Therapeutics, Inc. (GLUE) Historical Enterprise Value (quarterly & annually)

How has GLUE Enterprise Value performed in the past?

The mean historical Enterprise Value of Monte Rosa Therapeutics, Inc. over the last ten years is 609.76M. The current 356.78M Enterprise Value has changed 5.75% with respect to the historical average. Over the past ten years (40 quarters), GLUE's Enterprise Value was at its highest in in the March 2021 quarter at 963.74M. The Enterprise Value was at its lowest in in the June 2021 quarter at -241958424.20.

Monte Rosa Therapeutics, Inc. (GLUE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Monte Rosa Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Monte Rosa Therapeutics, Inc. (GLUE) Average Enterprise Value

How has GLUE Enterprise Value performed in the past?

The current Enterprise Value of Monte Rosa Therapeutics, Inc. (GLUE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Monte Rosa Therapeutics, Inc. (GLUE) Enterprise Value vs. Peers

How is GLUE’s Enterprise Value compared to its peers?

Monte Rosa Therapeutics, Inc.’s Enterprise Value is greater than Nkarta, Inc. (204.91M), greater than Lyell Immunopharma, Inc. (131.00M), greater than Generation Bio Co. (145.59M), greater than Sana Biotechnology, Inc. (333.02M), greater than Design Therapeutics, Inc. (323.81M), greater than Werewolf Therapeutics, Inc. (-16084776.00), greater than Ikena Oncology, Inc. (43.80M), less than Stoke Therapeutics, Inc. (467.23M), greater than Foghorn Therapeutics Inc. (255.47M), greater than Shattuck Labs, Inc. (12.30M), less than Kymera Therapeutics, Inc. (2.62B), less than Nurix Therapeutics, Inc. (1.34B), less than Gracell Biotechnologies Inc. (5.66B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Erasca, Inc. (685.22M),

Build a custom stock screener for Monte Rosa Therapeutics, Inc. (GLUE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monte Rosa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monte Rosa Therapeutics, Inc. (GLUE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monte Rosa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.